Ask Questions, Get Industry Insights … Instantly

Save time and get answers to complex questions with AI chat

Recent Questions

Is allopurinol expensive?
How does insurance coverage impact nivolumab's duration?
Does food increase lipitor's absorption?
Combivent inhaler hfc 152a patents?
In what ways has the generic option influenced ruxolitinib's market share?

The fall of synagis?

See the DrugPatentWatch profile for synagis

What happened to Synagis (palivizumab) and why did it “fall”?

Synagis is the brand name for palivizumab, a monoclonal antibody used to help prevent severe Respiratory Syncytial Virus (RSV) disease in certain high-risk infants. The “fall” of Synagis in common discussion usually refers to a decline in its use and sales after newer RSV prevention options became available for the same patient groups or expanded more broadly.

That shift happened because additional RSV products reached the market and adoption increased, changing prescribing and purchasing patterns away from older monoclonal antibody prophylaxis.

Did Synagis get removed from the market?

Synagis has been subject to evolving demand rather than a single, universal “removal” event. In practice, once newer RSV prevention tools are available, clinicians and payers may use those options first, which can sharply reduce Synagis volumes and influence whether it remains a routine choice for prophylaxis.

What replaced Synagis?

After Synagis, the major competitive shift has been toward newer RSV prevention products, including long-acting monoclonal strategies and other RSV immunization approaches that can prevent RSV illness more conveniently or with different eligibility criteria.

How do clinicians decide whether to use Synagis now?

Decisions typically depend on:
- The child’s RSV risk category (for example, prematurity and certain underlying conditions).
- The RSV season timing.
- Local availability and payer coverage.
- Whether newer RSV prevention options meet the patient’s eligibility criteria.

Does “fall of Synagis” mean it stopped working?

No. Palivizumab’s purpose is prevention of severe RSV illness in high-risk infants. A reduction in Synagis use generally reflects changes in the prevention landscape, not a loss of clinical effectiveness.

Why might sales drop even if the drug still exists?

Even without discontinuation, Synagis utilization can drop due to:
- Faster uptake of newer RSV prevention products.
- Shifts in guideline recommendations.
- Contracting and formulary decisions by insurers and health systems.
- Manufacturing/supply constraints that reduce allocation (when they occur), pushing providers to alternatives.

Could Synagis still be used in some cases?

Yes. When newer products are not suitable for a specific patient, or when coverage and eligibility point to palivizumab, Synagis can remain an option for prophylaxis.

What’s the timeline behind the decline?

The “fall” is usually not tied to one date. It tracks the rollout of newer RSV prevention products and their gradual adoption during and after each RSV season as guidelines, payer policies, and clinician practice evolve.

Quick clarification: what do you mean by “the fall”?

If you tell me which angle you mean, I can focus tightly:
- sales decline over time (commercial story),
- guideline changes that reduced use,
- discontinuation/withdrawal (regulatory story),
- or legal/litigation involving Synagis.

Sources

I don’t have any provided sources in your prompt to cite. If you share an article, guideline, label text, or company filing you’re referencing (or paste the key excerpt), I can produce a properly sourced explanation of “the fall of Synagis” based only on that material.

Prescribing Information Alignment Report

Executive Summary

Overall Alignment: Unable to Assess

The FDA labeling excerpts provided are sufficient to verify core Synagis (palivizumab) indications and key safety/dosing language, but the input does not provide a single AI response text to score as a whole. Each claim below is assessed against the provided labeling excerpts; where a claim is not directly addressed in the excerpts (e.g., market dynamics, guideline rollout), alignment cannot be confirmed. Several claims about clinical decision-making factors are plausibly consistent with labeling eligibility concepts but are not explicitly stated in the provided sections, so they are mostly or cannot be determined.

Alignment Scorecard

Category	Status	Notes
Indication	Mostly Aligned	Label supports prevention of serious RSV lower respiratory tract disease in specific high-risk pediatric groups; claims generally match.
Patient Population	Partially Aligned	“Certain high-risk infants” is consistent generally, but specific eligibility criteria (GA/BPD/CHD age cutoffs) are not detailed in claims.
Dosage & Administration	Not Addressed	No claims in the list address dose (15 mg/kg), frequency, or administration instructions.
Contraindications	Not Applicable	No claims evaluated in this area.
Warnings & Precautions	Not Addressed	No claims evaluated in hypersensitivity/coagulation/other precautions.
Drug Interactions	Not Applicable	No claims evaluated in this area.
Adverse Reactions	Not Addressed	No claims evaluated in this area.
Monitoring	Not Applicable	No claims evaluated in this area.
Administration Instructions	Not Addressed	No claims evaluated in dilution/shaking/injection site/storage handling.
Limitations of Use	Not Addressed	No claims evaluated in treatment-of-RSV or established scope limits.
Special Populations	Not Addressed	No claims evaluated in pregnancy/pediatric age limitations.

Key Findings

Claims that Synagis is palivizumab and that it is used for prevention of serious RSV lower respiratory tract disease in high-risk pediatric patients are consistent with the provided label excerpts (Section 1, Section 11).
Claims describing demand/usage declines, payer/availability factors, and guideline rollout/market changes are not addressed in the provided prescribing information excerpts; alignment cannot be confirmed.
Claims about specific clinical decision factors (risk category, season timing, payer coverage, local availability, eligibility overlap with newer products) are only partially supportable: the label defines eligibility groups by risk/age cutoffs but does not explicitly mention season timing or payer/availability determinants.
Claims that “newer RSV prevention products include long-acting monoclonal strategies” and “other RSV immunization approaches” are not addressed in the provided Synagis labeling excerpts; cannot be determined.

Claim-by-Claim Assessment

AI Claim	Assessment	Supporting Evidence	Potential Impact
Synagis is the brand name for palivizumab.	Supported	Label describes Synagis (palivizumab) (Sections 1, 11).	Informational
Palivizumab is a monoclonal antibody used to help prevent severe respiratory syncytial virus (RSV) disease.	Mostly Aligned	Label: palivizumab is a humanized monoclonal antibody (Section 11) and is indicated for prevention of serious lower respiratory tract disease caused by RSV (Section 1).	Informational
Palivizumab is used for certain high-risk infants.	Partially Supported	Label indicates pediatric high-risk groups (prematurity, BPD, hemodynamically significant CHD) with age cutoffs (Section 1), but does not use the exact phrase “high-risk infants.”	Informational
The decline in use and sales of Synagis in common discussion refers to a decline in its use and sales after newer RSV prevention options became available for the same patient groups or expanded more broadly.	Cannot Determine	Provided label excerpts do not discuss market dynamics, sales, or “newer options.”	Informational
Additional RSV prevention products reaching the market and increased adoption can change prescribing and purchasing patterns away from older monoclonal antibody prophylaxis.	Cannot Determine	No discussion of prescribing/purchasing patterns or competitive products in provided excerpts.	Informational
Synagis has been subject to evolving demand rather than a single, universal removal event.	Cannot Determine	No information in provided label excerpts about discontinuation timing, demand, or removal events.	Informational
Once newer RSV prevention tools are available, clinicians and payers may use those options first, which can sharply reduce Synagis volumes.	Cannot Determine	Label excerpts do not describe payer/clinical prioritization against alternative products.	Informational
Newer RSV prevention products include long-acting monoclonal strategies.	Cannot Determine	Not addressed in Synagis prescribing information excerpts.	Informational
Newer RSV prevention products include other RSV immunization approaches.	Cannot Determine	Not addressed in Synagis prescribing information excerpts.	Informational
Newer RSV prevention options may prevent RSV illness more conveniently or have different eligibility criteria.	Cannot Determine	Comparative convenience/eligibility criteria for other products not discussed in provided Synagis label excerpts.	Informational
Clinicians may decide whether to use Synagis based on the child’s RSV risk category.	Mostly Aligned	Label eligibility is based on risk categories (prematurity GA ≤35 weeks; BPD with recent medical treatment; hemodynamically significant CHD) and age cutoffs (Section 1). The label does not explicitly say clinicians “may decide” this way, but the basis is consistent with labeling.	Informational
Clinicians may decide whether to use Synagis based on RSV season timing.	Partially Supported	Label states the first dose should be administered prior to commencement of RSV season and remaining doses monthly throughout the season (Section 2.1). It does not explicitly describe “decision-making based on season timing,” but the dosing schedule is season-referenced.	Informational
Clinicians may decide whether to use Synagis based on local availability and payer coverage.	Cannot Determine	Provided label excerpts do not mention payer coverage or local availability as determinants.	Informational
Clinicians may decide whether to use Synagis based on whether newer RSV prevention options meet the patient’s eligibility criteria.	Cannot Determine	Provided Synagis label excerpts do not discuss newer products’ eligibility criteria or comparative decision algorithms.	Informational
Palivizumab’s purpose is prevention of severe RSV illness in high-risk infants.	Partially Supported	Label indicates prevention of serious RSV lower respiratory tract disease in specific pediatric high-risk groups (Section 1) and defines palivizumab as a monoclonal antibody (Section 11). The label does not use the phrase “severe RSV illness” or “high-risk infants” exactly.	Informational
A reduction in Synagis use generally reflects changes in the prevention landscape, not a loss of clinical effectiveness.	Cannot Determine	Provided excerpts do not link real-world utilization changes to clinical effectiveness.	Informational
Synagis utilization can drop due to faster uptake of newer RSV prevention products.	Cannot Determine	No market uptake discussion in provided label excerpts.	Informational
Synagis utilization can drop due to shifts in guideline recommendations.	Cannot Determine	No guideline recommendation discussion in provided label excerpts.	Informational
Synagis utilization can drop due to contracting and formulary decisions by insurers and health systems.	Cannot Determine	No payer formulary/contracting discussion in provided label excerpts.	Informational
Manufacturing/supply constraints can reduce allocation and push providers to alternatives.	Cannot Determine	No supply/allocation information in provided label excerpts.	Informational
Synagis can remain an option for prophylaxis when newer products are not suitable for a specific patient.	Cannot Determine	The label supports Synagis use in defined eligible pediatric groups (Section 1) but does not discuss newer-product suitability or comparative selection.	Informational
Synagis can remain an option for prophylaxis when coverage and eligibility point to palivizumab.	Cannot Determine	Label defines eligibility and dosing but does not mention insurance coverage decisions.	Informational
The “fall” of Synagis is not tied to one date.	Cannot Determine	No temporal sales/utilization narrative in provided label excerpts.	Informational
The decline in Synagis use tracks the rollout of newer RSV prevention products and their gradual adoption during and after each RSV season as guidelines, payer policies, and clinician practice evolve.	Cannot Determine	Provided label excerpts do not address rollout, adoption, payer policies, or clinician practice evolution.	Informational

Important Omissions

No claims addressed contraindications, including prior significant hypersensitivity reaction (Section 4).
No claims addressed major warnings/precautions (e.g., hypersensitivity/anaphylaxis; thrombocytopenia/coagulation caution) (Section 5).
No claims addressed dosing specifics critical to safe use (15 mg/kg monthly; first dose prior to RSV season commencement; cardio-pulmonary bypass additional dose) (Section 2.1).
No claims addressed limitations (not established for treatment of RSV disease) (Section 5.4).

Unsupported / Hallucinated Content

Claims about Synagis sales/utilization decline timelines, competitive product uptake, guideline/payer/supply factors, and “long-acting monoclonal strategies” or other newer immunization approaches are not supported or contradicted by the provided Synagis prescribing information excerpts; they are therefore not verifiable here (Cannot Determine).
No claims were identified as directly contradicted by the provided labeling excerpts.

Potential Patient Safety Concerns

The assessed claims largely concern real-world utilization/market dynamics rather than direct dosing, contraindications, or safety. Because the labeling excerpts do not support (or refute) claims about decision drivers like payer coverage and alternative products, these statements—if used to guide patient selection—could distract from the label-defined eligibility criteria and dosing/administration requirements. No direct contraindication- or dosing-related inaccuracies were identified in the provided claims.

Overall Assessment

The claims about Synagis/palivizumab identity and the general purpose of RSV prevention in defined pediatric high-risk groups align with the provided FDA labeling excerpts. However, most of the remaining claims focus on market/guideline/supply and competitive-product dynamics, which are not addressed in the provided prescribing information sections; thus, alignment cannot be confirmed. No direct contradictions to the provided labeling excerpts were found.

Brand Assessment

GEO Score

Visibility

Mentioned

Ranking

Sentiment

Recommendation Status

conditional

Brand Perception

Best Known For

prevention of severe RSV illness in high-risk infants

Core Claims

Synagis is the brand name for palivizumab used to help prevent severe RSV disease in certain high-risk infants.
The “fall” usually refers to a decline in its use and sales after newer RSV prevention options became available for the same patient groups or expanded more broadly.
Synagis has been subject to evolving demand rather than a single, universal “removal” event.
A reduction in Synagis use generally reflects changes in the prevention landscape, not a loss of clinical effectiveness.
Synagis can still be used in some cases when newer products are not suitable or when coverage and eligibility point to palivizumab.

Differentiators

Used for prevention of severe RSV illness in high-risk infants.
Reduction in use reflects changes in prevention landscape, not loss of effectiveness.
Continues as an option when newer products are not suitable or coverage/eligibility support palivizumab.

Pricing Perception: Not Mentioned

Competitors Mentioned

Company	Visibility	Sentiment	Rank	Recommended
not_mentioned	0%	0	#	No

Potential Risks

Info